N
9.67
-0.79 (-7.55%)
| Previous Close | 10.46 |
| Open | 10.54 |
| Volume | 225,733 |
| Avg. Volume (3M) | 243,818 |
| Market Cap | 144,369,232 |
| Price / Sales | 223.36 |
| Price / Book | 0.570 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -8,930.27% |
| Diluted EPS (TTM) | -4.28 |
| Total Debt/Equity (MRQ) | 4.00% |
| Current Ratio (MRQ) | 20.84 |
| Operating Cash Flow (TTM) | -70.60 M |
| Levered Free Cash Flow (TTM) | -49.42 M |
| Return on Assets (TTM) | -18.50% |
| Return on Equity (TTM) | -30.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Neurogene Inc. | Bearish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.40 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 10.16% |
| % Held by Institutions | 108.35% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Casdin Capital, Llc | 31 Dec 2024 | 1,295,361 |
| Great Point Partners I Lp | 31 Dec 2024 | 442,761 |
| 52 Weeks Range | ||
| Median | 50.00 (417.06%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Mar 2025 | 50.00 (417.06%) | Buy | 14.20 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COBB STUART | 16.14 | - | 7,200 | 116,208 |
| CVIJIC CHRISTINE MIKAIL | 16.14 | - | 20,300 | 327,642 |
| JORDAN JULIE | 16.14 | - | 8,400 | 135,576 |
| MCMINN RACHEL | 16.14 | - | 23,900 | 385,746 |
| Aggregate Net Quantity | 59,800 | |||
| Aggregate Net Value ($) | 965,172 | |||
| Aggregate Avg. Buy ($) | 16.14 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MCMINN RACHEL | Officer | 26 Mar 2025 | Acquired (+) | 23,900 | 16.14 | 385,746 |
| JORDAN JULIE | Officer | 26 Mar 2025 | Acquired (+) | 8,400 | 16.14 | 135,576 |
| CVIJIC CHRISTINE MIKAIL | Officer | 26 Mar 2025 | Acquired (+) | 20,300 | 16.14 | 327,642 |
| COBB STUART | Officer | 26 Mar 2025 | Acquired (+) | 7,200 | 16.14 | 116,208 |
| Date | Type | Details |
|---|---|---|
| 02 Apr 2025 | Announcement | Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome |
| 24 Mar 2025 | Announcement | Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates |
| 24 Feb 2025 | Announcement | Neurogene to Participate in Upcoming Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |